Vetter aligns development service laboratory portfolio under one roof
Bundling of competencies optimizes workflow of customer projects.
Vetter has brought together its development laboratories in one Ravensburg site end of last year.
Designed to improve workflow and enhance customer benefits within the daily support in complex development projects, the services at the 1,800-m2 building include process development as well as functional and specification testing of packaging systems, chemical-analytical and biochemical analysis and particle characterization. State-of-the-art non-GMP laboratory space and equipment combined with a leading-edge GMP analytical laboratory now allow for increased capacity and optimized work spaces.
At present, more than 50 employees work in the new labs. By bringing the laboratories under one roof, employees easily share expertise and know-how to improve and simplify information exchange, leverage synergies and reinforce a positive work atmosphere. Overall, customers will benefit from the alignment. Prior to the bundling of its laboratories, the development studies and the corresponding analytical services for testing during process or packaging material development took place in several labs at different locations in Ravensburg and Langenargen. By sequencing these services, processes have been synchronized and handling issues reduced, all leading to numerous benefits primarily for customer projects, but also for projects undertaken within the company.
“Our customers are excited and impressed with the new and modern development laboratories and their increased capacity. Now they can follow a complete development process and its individual steps, since it proceeds throughout the labs, all within the same building,” said Dr Claus Feussner, Senior Vice President Development Service. Expansion will continue within the building throughout the year and includes additional lab space, innovative analytical equipment and lyophilizer capacity.
Vetter is also committed to further process optimization and capacity expansion in filling and secondary packaging of injectables at all its sites. This is based on increased global customer demand for the development and commercialization of promising new compounds.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance